Micro-Cap Longevity Health Puts Itself Up for Strategic Review, Halts Bone-Repair R&D
XAGE sits 24% above its 52-week low of $0.101.
Summary
Longevity Health Holdings' board is exploring strategic alternatives for its bio-aesthetic and therapeutic businesses, a formal process that typically precedes a sale, merger, or wind-down. Separately, the company paused research and development on its regenerative bone and tissue healing products, shelving a core pipeline program. The company is a nano-cap trading around $0.125, so any transaction would be small in absolute dollars but could be decisive for equity holders. No terms, buyer, timeline, or financial details were disclosed, which limits how much can be priced in today.
At the time of this announcement, XAGE was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $309.4K. The 52-week trading range was $0.10 to $8.27. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.